Relmada Therapeutics (RLMD) Gains from Investment Securities (2014 - 2026)
Relmada Therapeutics (RLMD) reported Gains from Investment Securities of $125.0 for Q1 2026, down 100.0% year-over-year from $11.3 million in Q1 2025, and up 100.12% quarter-over-quarter from -$107924.0 in Q4 2025.
Relmada Therapeutics (RLMD) Gains from Investment Securities (2014 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 11 years of Gains from Investment Securities data on file, last reported at $125.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $125.0, down 100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $125.0 (down 100.0% YoY), and the FY2025 annual result was $5.4 million, up 4840.11% from the prior year.
- Gains from Investment Securities grew to $125.0 in Q1 2026 per RLMD's latest filing, from -$107924.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $13.1 million in Q2 2024 and troughed at -$3.3 million in Q4 2023.
- A 5-year average of $2.4 million and a median of $40844.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities slumped 9932.59% in 2023, then soared 8010.27% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$33351.0 in 2022, then tumbled by 9932.59% to -$3.3 million in 2023, then jumped by 101.22% to $40844.0 in 2024, then slumped by 364.23% to -$107924.0 in 2025, then soared by 100.12% to $125.0 in 2026.
- Business Quant data shows RLMD's Gains from Investment Securities at $125.0 in Q1 2026, -$107924.0 in Q4 2025, and -$81438.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.00 |
| Mar 31, 2026 | 125.00 |
| Dec 31, 2025 | -107,924.00 |
| Dec 31, 2025 | -107,924.00 |
| Sep 30, 2025 | -81,438.00 |
| Sep 30, 2025 | -81,438.00 |
| Jun 30, 2025 | 3.10 Mn |
| Jun 30, 2025 | 3.10 Mn |
| Mar 31, 2025 | 11.26 Mn |
| Mar 31, 2025 | 11.26 Mn |
| Dec 31, 2024 | 40,844.00 |
| Dec 31, 2024 | 40,844.00 |
| Sep 30, 2024 | 13.05 Mn |
| Sep 30, 2024 | 13.05 Mn |
| Jun 30, 2024 | 13.05 Mn |
| Jun 30, 2024 | 13.05 Mn |
| Mar 31, 2024 | 3.96 Mn |
| Mar 31, 2024 | 3.96 Mn |
| Dec 31, 2023 | -3.35 Mn |
| Dec 31, 2023 | -3.35 Mn |